600285 羚锐制药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,147,9772.32%3,853,3913,500,8313,311,4733,001,862
减:营业总成本1,588,8390.55%3,029,6712,768,1492,683,3042,584,417
    其中:营业成本453,24715.63%769,552846,562884,387832,114
               财务费用(7,154)72.83%(5,090)(18,885)(35,120)(26,588)
               资产减值损失(337)843.30%(608)(502)(2,873)(171)
公允价值变动收益2,447-222.45%(7,325)(10)1215,926
投资收益21,806-9.64%49,99640,21420,15458,655
    其中:对联营企业和合营企业的投资收益(68)-20.24%(426)1,824(385)43,350
营业利润578,8654.97%887,274810,302656,307517,121
利润总额577,3114.67%879,466827,573653,044517,035
减:所得税费用79,4564.99%117,018104,98884,92851,730
净利润497,8554.62%762,448722,585568,116465,305
减:非控股权益2,76486.39%2,9453460
股东净利润495,0914.36%759,503722,551568,109465,305

市场价值指针
每股收益 (元) *0.8744.55%1.3401.2871.0120.836
每股派息 (元) *----1.1000.9000.8000.600
每股净资产 (元) *5.6985.39%5.9965.4184.9214.495
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容